stockrow
Friday 6 November 2026
Export DNLI’s income statement to Excel — free account
Denali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
20.12
0.40
+2.03%
Follow DNLI
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 7 | 2 | 4 | 4 | — | — |
P/E ratio |
— | — | 0.00 | 0.00 | 214.77 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z-Score |
— | — | 10.27 | 4.85 | 13.16 | 6.50 | 4.22 | 13.78 | — | — |
P/S ratio |
— | — | 14.82 | 62.43 | 27.19 | 111.38 | 31.98 | 8.89 | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | 7.83 | 2.08 | 8.03 | 1.80 | 3.41 | 10.11 | — | — |
P/FCF ratio |
— | — | 40.96 | 0.00 | 22.10 | 0.00 | 0.00 | 0.00 | — | — |
P/Operating CF |
— | — | 20.54 | (34.96) | 17.76 | (82.76) | (47.73) | (29.78) | — | — |
P/B ratio |
— | — | 3.50 | 4.22 | 7.93 | 5.63 | 3.33 | 2.85 | — | — |
Price to Tangible BV |
— | — | 3.50 | 4.22 | 7.93 | 5.63 | 3.33 | 2.85 | — | — |
EV/Sales |
— | — | 11.22 | 49.45 | 23.01 | 94.81 | 20.15 | 5.90 | — | — |
EV/EBITDA |
— | — | 0.00 | 0.00 | 108.30 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
— | — | 28.92 | (8.70) | 18.56 | (21.83) | (8.93) | (5.45) | — | — |
EV/FCF |
— | — | 31.02 | (7.78) | 18.69 | (20.98) | (8.32) | (5.26) | — | — |
Quick Ratio |
19.58 | 28.68 | 14.16 | 9.16 | 20.50 | 2.29 | 3.67 | 13.27 | 8.14 | 8.82 |
Current Ratio |
19.98 | 28.92 | 14.67 | 9.48 | 20.86 | 2.37 | 3.77 | 13.65 | 8.46 | 9.16 |
Net Debt/EBITDA |
2.08 | 4.71 | 11.14 | 1.65 | (19.71) | 2.90 | 3.87 | 4.62 | 1.61 | 1.56 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 12.47% | 3.99% | 4.20% | 3.63% | 0.00% | 0.41% | 0.48% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.17 | 0.06 | 0.06 | 0.05 | 0.00 | 0.00 | 0.01 |
Asset Turnover |
0.00 | 0.00 | 0.22 | 0.04 | 0.31 | 0.03 | 0.08 | 0.25 | 0.00 | 0.00 |
Operating CF/Net income |
0.83 | 0.87 | (1.38) | 0.77 | 5.85 | 0.73 | 0.75 | 2.47 | 0.82 | 0.81 |
Capex/Depreciation |
(3.46) | (0.75) | (0.72) | (6.03) | (0.36) | (0.49) | (2.04) | 0.48 | 0.58 | (10.22) |
| 157.85% | (47.46%) | (7.16%) | (41.97%) | 9.21% | (27.51%) | (32.52%) | (14.01%) | (37.40%) | (45.69%) | |
| (56.31%) | (23.27%) | (6.31%) | (32.52%) | 6.59% | (19.32%) | (22.76%) | (11.11%) | (33.45%) | (40.69%) | |
ROIC |
(71.72%) | (94.57%) | (35.11%) | (274.53%) | 0.00% | (118.58%) | 0.00% | 0.00% | (75.59%) | (229.23%) |
Return on Tangible Assets |
(46.06%) | (21.49%) | (7.66%) | (45.81%) | 4.86% | (52.09%) | (30.97%) | (14.08%) | (51.72%) | (59.97%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 110.86% | 724.87% | 63.34% | 545.31% | 330.74% | 128.24% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 25.05% | 174.23% | 17.97% | 162.47% | 83.42% | 31.27% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 14.55% | 143.86% | 15.00% | 175.19% | 92.06% | 32.71% | 0.00% | 0.00% |
Graham Net Nets |
— | — | 0.19 | 0.16 | 0.11 | 0.08 | 0.28 | 0.32 | — | — |
Graham Number |
— | — | 0.00 | 0.00 | 9.63 | 0.00 | 0.00 | 0.00 | — | — |
Earnings Yield |
— | — | (1.98%) | (11.83%) | 0.47% | (5.36%) | (9.41%) | (4.86%) | — | — |
Free Cash Flow Yield |
— | — | 2.44% | (10.18%) | 4.53% | (4.06%) | (7.57%) | (12.62%) | — | — |
Revenue per Share |
0.00 | 0.00 | 1.39 | 0.28 | 3.08 | 0.40 | 0.86 | 2.41 | 0.00 | 0.00 |
Operating CF per Share |
(11.19) | (5.12) | 0.54 | (1.59) | 3.82 | (1.74) | (1.95) | (2.61) | (2.11) | (2.39) |
Capex per Share |
(0.95) | (0.19) | (0.04) | (0.19) | (0.03) | (0.07) | (0.14) | (0.09) | (0.10) | (0.05) |
Free Cash Flow per Share |
(12.15) | (5.31) | 0.50 | (1.77) | 3.79 | (1.81) | (2.09) | (2.70) | (2.21) | (2.44) |
Cash per Share |
27.76 | 27.15 | 5.01 | 4.34 | 13.49 | 7.12 | 10.64 | 7.53 | 5.06 | 5.03 |
Shareholders Equity per Share |
39.61 | 31.13 | 5.90 | 4.13 | 10.56 | 7.92 | 8.30 | 7.50 | 7.48 | 5.87 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
39.61 | 31.13 | 5.90 | 4.13 | 10.56 | 7.92 | 8.30 | 7.50 | 7.48 | 5.87 |
Free Cash Flow |
(78.04) | (79.51) | 46.72 | (169.49) | 413.06 | (219.89) | (262.55) | (370.93) | (363.61) | (422.10) |
Working Capital |
172.85 | 395.44 | 448.05 | 384.69 | 1,423.96 | 518.99 | 1,008.40 | 986.16 | 762.23 | 802.31 |
Capital Expenditures |
(6.13) | (2.87) | (3.39) | (17.92) | (3.09) | (8.50) | (17.83) | (12.94) | (15.91) | (9.50) |
Net Current Asset Value |
165.41 | 388.68 | 365.70 | 271.69 | 1,041.91 | 455.36 | 954.51 | 941.17 | 719.94 | 769.57 |
EV/EBIT |
— | — | 0.00 | 0.00 | 123.12 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.00 | 0.00 | 0.03 | 0.67 | 0.01 | 0.17 | 0.16 | 0.04 | 0.00 | 0.00 |
Price to Operating Income |
— | — | 0.00 | 0.00 | 145.54 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.12 | 0.26 | 0.19 | 0.06 | 0.21 | 0.45 | 0.20 | (0.60) | (0.49) | 0.02 |
Cash ROIC |
(18.03%) | (9.12%) | 4.62% | (19.28%) | 15.39% | (11.65%) | (10.80%) | (17.96%) | (17.59%) | (22.37%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 28.70 | 0.00 | 0.00 | 4.06 | 10.85 | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.00 | 0.00 | 4.50 | — | — | 12.00 | 10.00 | — | — | — |
Average Payables |
1.84 | 2.34 | 2.30 | 2.24 | 1.83 | 2.93 | 3.78 | 6.14 | 10.31 | 7.23 |
Average Assets |
153.88 | 378.89 | 574.35 | 607.61 | 1,078.76 | 1,504.22 | 1,432.20 | 1,307.08 | 1,264.05 | 1,259.52 |
Average Common Equity |
(54.89) | 185.82 | 506.32 | 470.87 | 772.71 | 1,056.41 | 1,002.36 | 1,036.69 | 1,130.32 | 1,121.72 |
Columns are period end dates · fundamentals updated 5 Nov 2026